Scholar Rock (NASDAQ:SRRK) Insider Mo Qatanani Sells 14,898 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Mo Qatanani sold 14,898 shares of the firm’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $46.71, for a total transaction of $695,885.58. Following the sale, the insider directly owned 85,660 shares in the company, valued at approximately $4,001,178.60. The trade was a 14.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Mo Qatanani also recently made the following trade(s):

• On Friday, January 16th, Mo Qatanani sold 8,406 shares of Scholar Rock stock. The stock was sold at an average price of $44.48, for a total transaction of $373,898.88.
• On Wednesday, January 14th, Mo Qatanani sold 13,112 shares of Scholar Rock stock. The shares were sold at an average price of $45.20, for a total transaction of $592,662.40.
• On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The stock was sold at an average price of $45.21, for a total transaction of $6,169,447.02.

Scholar Rock Price Performance

Shares of SRRK opened at $44.29 on Friday. The firm has a fifty day simple moving average of $43.73 and a two-hundred day simple moving average of $37.30. The firm has a market cap of $4.52 billion, a PE ratio of -14.06 and a beta of 0.63. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a 1-year low of $22.71 and a 1-year high of $48.28.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period in the previous year, the firm posted ($0.66) earnings per share. On average, equities analysts anticipate that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Barclays upped their target price on shares of Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. Bank of America assumed coverage on shares of Scholar Rock in a research note on Thursday, October 9th. They set a “buy” rating and a $53.00 price target on the stock. Citigroup initiated coverage on Scholar Rock in a research note on Friday, January 9th. They issued a “buy” rating and a $55.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday. Four investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $50.14.

Hedge Funds Weigh In On Scholar Rock

A number of hedge funds have recently modified their holdings of SRRK. Wellington Management Group LLP raised its position in shares of Scholar Rock by 124.5% during the 3rd quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock valued at $169,289,000 after purchasing an additional 2,521,022 shares during the period. Holocene Advisors LP purchased a new stake in Scholar Rock in the 3rd quarter worth $91,670,000. Norges Bank bought a new stake in Scholar Rock during the second quarter valued at about $41,628,000. Balyasny Asset Management L.P. purchased a new position in shares of Scholar Rock in the second quarter valued at about $33,062,000. Finally, UBS Group AG boosted its stake in shares of Scholar Rock by 233.8% in the third quarter. UBS Group AG now owns 1,131,787 shares of the company’s stock worth $42,148,000 after acquiring an additional 792,760 shares during the period. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).